DrugInformations.org

Australian biotechnology company Avexa (ASX:AVX) today announced that it has completed recruitment of the first 160 patients for the two-dose component of its Phase III trial for apricitabine (ATC), with over 300 patients in the screening or dosing stages of the trial. The trial is ongoing with over 130 specialist HIV centres in 15 countries and results from this component of the trial are expected in the second quarter of 2009.

More: continued here

No Comments »

When a pregnant woman goes into early labor, her obstetrician may give her drugs to quiet the woman’s uterus and prevent premature birth. New research shows, however, that one popular drug works no better than a placebo at maintaining pregnancy after the initial bout of preterm labor is halted, say scientists at the Stanford University School of Medicine, Lucile Packard Children’s Hospital and Santa Clara Valley Medical Center.

More: continued here

No Comments »

Schering-Plough Corporation (NYSE: SGP) reported that preladenant, its novel and selective adenosine2a receptor antagonist, met the primary endpoint in a Phase II dose-finding trial in patients suffering from moderate to severe Parkinson’s disease experiencing motor fluctuations and abnormal involuntary movements (dyskinesias). The trial results were presented at the company’s 2008 R&D Update meeting being hosted for analysts and portfolio managers at company headquarters.

More: continued here

No Comments »